GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (FRA:VSC) » Definitions » Profitability Rank

4SC AG (FRA:VSC) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is 4SC AG Profitability Rank?

4SC AG has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

4SC AG's Operating Margin % for the quarter that ended in Dec. 2023 was -2,045.76%. As of today, 4SC AG's Piotroski F-Score is 3.


Competitive Comparison of 4SC AG's Profitability Rank

For the Biotechnology subindustry, 4SC AG's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4SC AG's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's Profitability Rank distribution charts can be found below:

* The bar in red indicates where 4SC AG's Profitability Rank falls into.



4SC AG Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

4SC AG has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

4SC AG's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-3.621 / 0.177
=-2,045.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

4SC AG has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

4SC AG operating margin has been in a 5-year decline. The average rate of decline per year is -38.2%.

4. Consistency of the profitability

5. Predictability Rank


4SC AG Profitability Rank Related Terms

Thank you for viewing the detailed overview of 4SC AG's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


4SC AG (FRA:VSC) Business Description

Traded in Other Exchanges
Address
Fraunhoferstraße 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG (FRA:VSC) Headlines

No Headlines